Opendata, web and dolomites

COSYN SIGNED

Comorbidity and Synapse Biology in Clinically Overlapping Psychiatric Disorders

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 COSYN project word cloud

Explore the words cloud of the COSYN project. It provides you a very rough idea of what is the project "COSYN" about.

syndrome    disease    utility    samples    clinical    intellectual    multiple    precisely    approved    id    bench    genomic    classification    mechanisms    editing    scaled    extensive    dysfunction    synapses    neurons    double    reproducibly    cellular    biology    decoding    correct    clinic    compound    cosyn    ameliorated    standard    medicine    capitalise    create    vitro    molecular    symptom    genetic    comorbidities    blinded    criteria    place    academic    person    genome    unravel    patients    neuronal    discriminate    crossover    disability    rare    refine    assays    medication    clinician    diagnostic    industry    carefully    therapeutics    overlap    alterations    integrates    tools    cells    variants    models    clue    schizophrenia    elucidate    synaptic    neurobiological    neuroscience    effect    platforms    understand    outstanding    patient    recommend    generate    autism    comorbidity    bedside    technologies    subtypes    indicated    screening    pharma    neurobiology    cell    personalised    precision    intensive   

Project "COSYN" data sheet

The following table provides information about the project.

Coordinator
KAROLINSKA INSTITUTET 

Organization address
address: Nobels Vag 5
city: STOCKHOLM
postcode: 17177
website: www.ki.se

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Project website http://www.cosyn-precisionmedicine.eu
 Total cost 6˙000˙000 €
 EC max contribution 5˙925˙000 € (99%)
 Programme 1. H2020-EU.3.1.1. (Understanding health, wellbeing and disease)
 Code Call H2020-PHC-2015-two-stage
 Funding Scheme RIA
 Starting year 2016
 Duration (year-month-day) from 2016-01-01   to  2020-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    KAROLINSKA INSTITUTET SE (STOCKHOLM) coordinator 675˙000.00
2    STICHTING VU NL (AMSTERDAM) participant 1˙925˙000.00
3    MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV DE (MUENCHEN) participant 800˙000.00
4    SYNAPTOLOGICS BV NL (AMSTERDAM) participant 650˙000.00
5    UNIVERSITATSKLINIKUM BONN DE (BONN) participant 600˙000.00
6    LIFE AND BRAIN GMBH DE (BONN) participant 300˙000.00
7    CARDIFF UNIVERSITY UK (CARDIFF) participant 225˙000.00
8    HELSINGIN YLIOPISTO FI (HELSINGIN YLIOPISTO) participant 225˙000.00
9    INSTITUT PASTEUR FR (PARIS CEDEX 15) participant 225˙000.00
10    CEGAT GMBH DE (TUBINGEN) participant 100˙000.00
11    H. LUNDBECK AS DK (VALBY) participant 75˙000.00
12    REGION HOVEDSTADEN DK (HILLEROD) participant 75˙000.00
13    VERENIGING SAMENWERKENDE OUDER- EN PATIENTENORGANISATIES NL (SOEST) participant 50˙000.00
14    F. HOFFMANN-LA ROCHE AG CH (BASEL) participant 0.00

Map

 Project objective

COSYN integrates outstanding European academic and three large Pharma to exploit genomic findings for intellectual disability (ID), autism, and schizophrenia. We capitalise on comorbidity, from clinic to cells and synapses, and have access to large existing samples. We focus on rare genetic variants of strong effect in patients with clinical comorbidity. Our aims are: (1) Understand comorbidity by comparing symptom and syndrome overlap with novel neurobiological criteria; (2) Elucidate mechanisms of comorbidity using neurobiology for the major genomic clue of synaptic dysfunction to unravel the cellular mechanisms of comorbidity; (3) Generate novel neuronal cell models by using advanced technologies to make neurons from carefully selected patients, and use genome editing to create or correct genetic variants. Multiple advanced neuroscience platforms are in place to evaluate an extensive set of molecular and cellular parameters, and to identify alterations in synaptic biology characteristic of ID, autism, and schizophrenia. These cellular models will, with Pharma partners, be up-scaled to provide “industry-standard” cellular assays for compound screening; (4) Refine diagnostic tools, use novel genomic and cellular features to improve disease classification and discriminate specific patient subtypes; and (5) Case studies in precision medicine: with Pharma partners, identify patients with a genetic change whose consequences can be reproducibly ameliorated in vitro by an approved medication. Recommend to the patient and clinician a double-blinded, N-of-one crossover case study to evaluate the clinical utility of a medication precisely indicated for that person. COSYN is an integrated, state-of-art, bench-to-bedside programme focused on personalised therapeutics. COSYN is a crucial next step in “decoding” the genetic findings via intensive focus on the clinical and molecular comorbidities of ID, autism, and schizophrenia.

 Deliverables

List of deliverables.
Outreach activities (debate) on the philosophy of using patient-own cells for a new generation of cellular models Documents, reports 2020-04-09 09:39:17

Take a look to the deliverables list in detail:  detailed list of COSYN deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "COSYN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "COSYN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.1.)

ENDpoiNTs (2019)

Novel Testing Strategies for Endocrine Disruptors in the Context of Developmental NeuroToxicity

Read More  

DECISION (2020)

DECOMPENSATED CIRRHOSIS: IDENTIFICATION OF NEW COMBINATORIAL THERAPIES BASED ON SYSTEMS APPROACHES

Read More  

BIND (2020)

Brain Involvement iN Dystrophinopathies

Read More